Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
How Incretin Drugs Affect the Heart
A new review finds heart benefits from incretin drugs like tirzepatide and retatrutide involve pathways beyond blood sugar control.
Incretin Drugs and the Sarcopenia Question
A new review argues that incretin drugs such as tirzepatide and semaglutide need built-in muscle monitoring alongside fat-loss tracking.
Novo sues Lilly over GLP-1 ad claims
Novo Nordisk sued Eli Lilly over GLP-1 ads it says compare Zepbound with lower-dose Wegovy. Here is what the false-advertising suit alleges.
Is a 'research use only' peptide legal?
A research use only label on a peptide vial does not answer whether a clinic can legally give it to a patient.
Semaglutide and Alzheimer's after EVOKE
Semaglutide failed both EVOKE Alzheimer's trials. A new paper argues research should shift from one hypothesis to a stratified program.
Cold exposure and tirzepatide: mouse study
A mouse study found intermittent cold exposure did not add to tirzepatide's weight-loss effect in obese mice.
Tirzepatide and Oral Contraceptives
A new review asks whether tirzepatide's slowed digestion could also blunt oral progestogens used beyond birth control pills.
Tirzepatide vs GLP-1RAs and IBD risk
A US propensity-matched study found tirzepatide linked to fewer IV steroid courses than other GLP-1 drugs among patients who already have IBD.
CT130: A GLP-1 Drug Built to Take Breaks
CT130 is a semaglutide-derived GLP-1 drug tested so far in mice and monkeys, not humans, built around scheduled drug-free intervals.
Why Dying Liver Cells Drive MASH
A 2026 review explains how cell death fuels MASH, the liver disease semaglutide became the first FDA-approved drug to treat.
GLP-1 Drugs, PCOS, and Stopping Treatment
Some GLP-1 users say PCOS symptoms return after stopping treatment. Here is what the semaglutide and retatrutide trial data actually shows.
Semaglutide and tirzepatide for MASH
Semaglutide now has FDA approval for MASH liver fibrosis, and tirzepatide's phase 2 data suggests a stronger signal is coming.